Phase 2 N=21 Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Advanced Gastric Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 Chronic Evaluation of Respicardia Therapy
Sleep Disordered Breathing · Cheyne Stokes Respiration · Periodic Breathing
Primary: AHI Change From Baseline at 3 Months — -27.1 events/hour — p=<.001
Phase 3 N=118 Phase III Study in Refractory Behcet's Disease
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
N/A N=80 The Use of Warmed Saline in Vaso-occlusive Episodes
Sickle Cell Disease · Sickle Cell Crisis
Primary: Rate of Hospital Admission — 63; 55 percentage of participants
N/A N=135 Effect of CPAP on Postoperative Delirium
Sleep Apnea, Obstructive · Delirium
Primary: Presence of Postoperative Delirium — 4.8; 5.1; 7.8; 8.1 units on a scale
Phase 2 N=121 Effect of Febuxostat on Blood Pressure
Hypertension
Primary: Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6 — 142.3; 139.5; -3.4; -3.7 millimeters of…
N/A N=24 Concurrent Treatment for Depressed Parents and DepressedAdolescents
Depression · Suicide
Primary: Beck Depression Inventory - Adolescent Report, Change in Symptom Level — -17.5; -14.1 change in BDI (-60 to 60 possible range) — p=.46
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 3 N=355 Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -5; -20.5; -44.1; -4.8 percent change — p=< 0.0001
Phase 3 N=559 A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — -0.44; 3.59; 2.16 percent predicted of FEV1 — p=<0.0001
Phase 3 N=462 Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events — 14; 3; 6; 6 participants
Phase 2 N=50 Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
Central Nervous System
Primary: Apparent Clearance (CL/F) of Perampanel [Core Study] — 0.732; 0.956; 1.73; 1.92 Liter per hour
N/A N=44 One-Day Acceptance and Commitment Training Intervention in Primary Care Patients
Mood Disorders · Hypertension · Diabetes
Primary: Mean Change in Participants World Health Organization Quality of Life Measure- Physical Score: Change From Baseline to 3 and 6 Month Follow-up. — .85; 2.8; 1.9; 4.1…
Phase 1 N=36 Asian Phase I Study Of PF-03446962
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 10.0 mg/kg
Phase 2 N=54 Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants